Through diligent and innovative work, to contribute to human health
Zhejiang Doer Biologics Co., Ltd. was established on April 1, 2014, with a registered capital of 52.12 million yuan. The company is a high-tech enterprise specializing in innovative biopharmaceutical development under Huadong Medicine (stock code: SZ.000963). Its R&D center is located in the Hangzhou Medicine Port Town.
Doer Biologics focuses on developing innovative multi-domain multispecific protein-based therapeutics to address unmet clinical needs in areas such as metabolic diseases and cancer. The company is one of the very few R&D-oriented enterprises in China with proprietary technology platforms dedicated to innovative biopharmaceutical development. The company possesses several proprietary protein engineering platforms, including the XLONGvlation® platform—a recombinant PEG-like (rPEG) protein half-life extension technology, the MultipleBody® multi-targeting technology platform, and the AccuBody® platform for precision cancer therapy. Leveraging these platforms, the company has developed multiple innovative multi-domain multispecific protein-based drug candidates and has licensed dozens of related invention patents both domestically and internationally. To date, five globally innovative products from its pipeline have entered different clinical stages in China and abroad.
The name "Doer" originates from "Dalton", the atomic mass unit that serves as the fundamental measure for all drugs. Though the smallest unit, it is also the most essential. Inspired by this, Doer Biologics is motivated to accumulate progress step by step through teamwork, striving ultimately to become a core force in China's independent innovative biopharmaceutical industry!
To date, the company has submitted over 70 patents related to innovative drugs, with several key international patents filed for protection in countries and regions including the United States, Europe, Japan, South Korea, Australia, and Canada. As of now, more than 40 invention patents have been granted.
The company's proprietary R&D achievements have gained continuous recognition from the international academic community. To date, multiple innovative research results have been published in authoritative journals and presented at academic conferences, reflecting the company's growing independent innovation capability.
The company is committed to cutting-edge innovative drug development and translational research. In 2024, it established a national postdoctoral research station and has been jointly training postdoctoral researchers in collaboration with mobile stations from universities such as Zhejiang University and Zhejiang University of Technology.
· National High-Tech Enterprise
· Zhejiang Provincial High-Tech Enterprise R&D Center
· Zhejiang Provincial Technology-based SME
· Hangzhou Intellectual Property Strong Enterprise
· Zhejiang Provincial Vanguard and Leading R&D Program
· Hangzhou High-Quality Development Initiative for the Biopharmaceutical Industry
· Qiantang District Leading Talent Team